BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Bayer AG (BAY.F) Bets $4 Billion on R8D and Sales From 5 Blockbuster Drugs


11/14/2012 7:17:10 AM

German pharmaceutical and chemical company Bayer AG (BAYN.XE) said Wednesday it sees peak annual sales potential of 5.5 billion euros ($7 billion) for its five new drugs Xarelto, Stivarga, Alpharadin, Aflibercept and Riociguat. Bayer now includes the new drug Riociguat, which helps to treat pulmonary hypertension, in its sales forecast. The company said late last year that it sees peak sales potential of at least EUR1 billion for the cancer drugs Alpharadin and Regorafenib, also known as Stivarga, as well as the eye medicine Aflibercept, also known as Eylea and VEGF Trap-Eye.

Read at News Release
Read at Reuters
Read at News Release

Bayer AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->